CN116492428A - A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases - Google Patents
A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN116492428A CN116492428A CN202310643162.6A CN202310643162A CN116492428A CN 116492428 A CN116492428 A CN 116492428A CN 202310643162 A CN202310643162 A CN 202310643162A CN 116492428 A CN116492428 A CN 116492428A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- traditional chinese
- rhizoma
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 33
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 31
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 59
- 210000000582 semen Anatomy 0.000 claims abstract description 32
- 241000628997 Flos Species 0.000 claims abstract description 28
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 24
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 17
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 16
- 239000009636 Huang Qi Substances 0.000 claims abstract description 15
- 244000268590 Euryale ferox Species 0.000 claims description 26
- 240000000249 Morus alba Species 0.000 claims description 13
- 235000008708 Morus alba Nutrition 0.000 claims description 13
- 240000007164 Salvia officinalis Species 0.000 claims description 13
- 240000008042 Zea mays Species 0.000 claims description 13
- 235000007244 Zea mays Nutrition 0.000 claims description 13
- 229940089639 cornsilk Drugs 0.000 claims description 13
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 239000001231 zea mays silk Substances 0.000 claims description 13
- 241000132012 Atractylodes Species 0.000 claims description 12
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 12
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 12
- 241000305492 Gastrodia Species 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 241000208688 Eucommia Species 0.000 claims description 11
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 11
- 240000008790 Musa x paradisiaca Species 0.000 claims description 11
- 235000015266 Plantago major Nutrition 0.000 claims description 11
- 229940107666 astragalus root Drugs 0.000 claims description 11
- 235000005412 red sage Nutrition 0.000 claims description 11
- 244000042430 Rhodiola rosea Species 0.000 claims description 10
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 10
- 244000185386 Thladiantha grosvenorii Species 0.000 claims description 10
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 10
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 9
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 9
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 9
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 9
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 9
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 9
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 9
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 9
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 9
- 240000000171 Crataegus monogyna Species 0.000 claims description 9
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 9
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 9
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 9
- 244000241838 Lycium barbarum Species 0.000 claims description 9
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 9
- 241000169546 Lycium ruthenicum Species 0.000 claims description 9
- 244000131316 Panax pseudoginseng Species 0.000 claims description 9
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 9
- 241000112528 Ligusticum striatum Species 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 241000212322 Levisticum officinale Species 0.000 claims description 5
- 239000001645 levisticum officinale Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000009759 San-Chi Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims 1
- 239000011802 pulverized particle Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 60
- 239000008280 blood Substances 0.000 abstract description 60
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 33
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 32
- 210000004185 liver Anatomy 0.000 abstract description 32
- 229940116269 uric acid Drugs 0.000 abstract description 32
- 210000003734 kidney Anatomy 0.000 abstract description 28
- 229940079593 drug Drugs 0.000 abstract description 18
- 210000000952 spleen Anatomy 0.000 abstract description 17
- 210000002216 heart Anatomy 0.000 abstract description 15
- 230000036772 blood pressure Effects 0.000 abstract description 13
- 238000005728 strengthening Methods 0.000 abstract description 13
- 210000002784 stomach Anatomy 0.000 abstract description 12
- 210000004072 lung Anatomy 0.000 abstract description 11
- 230000003750 conditioning effect Effects 0.000 abstract description 7
- 210000004556 brain Anatomy 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 241000600871 Euryale <brittle star> Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 26
- 206010020772 Hypertension Diseases 0.000 description 23
- 230000007812 deficiency Effects 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 16
- 235000009508 confectionery Nutrition 0.000 description 15
- 235000019197 fats Nutrition 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 239000002220 antihypertensive agent Substances 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 229940127088 antihypertensive drug Drugs 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 201000001431 Hyperuricemia Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 241001165494 Rhodiola Species 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010067286 Left atrial dilatation Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- -1 ni Gu Suan Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 244000237330 gutta percha tree Species 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 241000722941 Achillea Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 206010051078 Lacunar infarction Diseases 0.000 description 1
- 206010024602 Lipiduria Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 1
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application provides a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine comprises the following traditional Chinese medicinal materials: radix Salviae Miltiorrhizae, radix Rhodiolae, stigma Maydis, rhizoma Chuanxiong, rhizoma Gastrodiae, cortex Eucommiae, flos Notoginseng, flos Chrysanthemi, semen Cassiae, radix astragali, rhizoma Atractylodis Macrocephalae, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii, and fructus Mori. The preparation method starts with clearing and dredging cardiovascular stasis, conditioning liver, kidney, heart, brain, lung, stomach and spleen, and is assisted with systematically combined strengthening body resistance medicine to improve the current situation of the organism, and finally the obtained traditional Chinese medicine composition can effectively reduce blood pressure, blood fat and uric acid, thereby preventing and treating cardiovascular and cerebrovascular diseases, conditioning liver, kidney, heart, brain, lung, stomach and spleen, and enabling the organism to reach normal health level without depending on medicines in later period.
Description
Technical Field
The application relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases.
Background
Cardiovascular and cerebrovascular diseases are the collective name for cardiovascular and cerebrovascular diseases, and common diseases include hyperlipidemia, atherosclerosis, hypertension, hyperuricemia and the like.
Hypertension, hyperlipidemia and hyperuricemia can have multiple effects on the body:
the effect of hypertension on the body is a clinical symptom causing discomfort such as dizziness, headache, cervical immobilization, fatigue, palpitation, etc. The biggest hazard of hypertension is damage to organs such as heart, brain, kidney and the like, thereby causing various complications of hypertension. The complications of hypertension are mainly the following:
1. cerebrovascular diseases, including cerebral hemorrhage, cerebral thrombosis, lacunar infarction, and transient ischemic attacks.
2. Causing symptoms such as heart failure, coronary atherosclerotic heart disease, coronary heart disease or cardiac hypertrophy.
3. Causing chronic renal insufficiency and aortic dissection.
4. The long-term administration of western antihypertensive drugs can lead to vasoconstriction, reduced blood supply to the heart, enlarged left atrium, gastrointestinal discomfort, liver and kidney damage and even complications.
The influence of hyperlipidemia on the body is:
1. impairment of liver function: the long-term hyperlipidemia not only can cause fatty liver, but also can cause atherosclerosis, and can cause great damage to liver functions of patients, thereby affecting the liver functions.
2. Causing coronary heart disease: when the fat content in human blood is high, partial fat can be deposited in blood vessels, atherosclerosis can possibly occur, blood vessels become narrower at the time, blood flow can be reduced, myocardial ischemia can be easily caused, and coronary heart disease can be caused.
3. Hypertension: the hyperlipidemia may also cause hypertension, mainly because the hyperlipidemia causes atherosclerosis of human body, causes dysfunction of cardiac muscle, promotes vasospasm, and increases secretion of vasopressin by adrenal glands, thereby causing hypertension.
4. Resulting in cerebral stroke: once hypertension is present, the blood vessel is easy to be in a spasticity state, and the cerebral blood vessel is easy to be damaged after hardening, so that the blood vessel is broken, and the occurrence of hemorrhagic cerebral apoplexy is further caused.
5. Obesity: the blood fat level exceeds the normal standard of a human body, which indicates that the regulation system of the body is disturbed, excessive fat is accumulated in blood, and a large amount of fat exists in subcutaneous tissues and tissues around the blood vessel wall, so that the fat supply and demand of the body are increased, and obesity is caused.
The effects of hyperuricemia on the body are:
1. most patients with hyperuricemia have gouty arthritis and symptoms such as swelling and pain, limited movement and the like.
2. Gouty kidney disease occurs when uric acid accumulates in the kidneys. Even kidney function impairment occurs.
3. Can cause blood circulation disorder, cause cardiovascular and cerebrovascular diseases and increase the probability of myocardial infarction and cerebral infarction.
The current medicines for treating hypertension, hyperlipidemia and hyperuricemia are mostly western medicines, such as diuretics, antihypertensives, vascular smooth muscle dilators, angiotensin converting enzyme inhibitors and the like, which are required to be taken by patients for a long time, and the long-term taking of western medicines has extremely high detoxification pressure on livers, but the current traditional Chinese medicines for treating cardiovascular and cerebrovascular diseases, which have the antihypertensive effect and simultaneously have the lipid-lowering and uric acid-lowering effects, are rare.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, which has the effects of promoting blood circulation to remove blood stasis, dredging collaterals, reducing blood pressure and blood lipid, tonifying kidney and liver, protecting stomach and strengthening spleen, can clear and dredge blood vessels to block, prevent thrombosis, eliminate and condition damage to other organs such as kidneys and hearts caused by long-term use of antihypertensive drugs, reduce blood pressure, blood lipid and blood uric acid, and control and prevent cardiovascular and cerebrovascular diseases.
The technical problem of the application is solved by adopting the following technical scheme.
In one aspect, the embodiment of the application provides a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, which comprises the following traditional Chinese medicinal materials: radix Salviae Miltiorrhizae, radix Rhodiolae, stigma Maydis, rhizoma Chuanxiong, rhizoma Gastrodiae, cortex Eucommiae, flos Notoginseng, flos Chrysanthemi, semen Cassiae, radix astragali, rhizoma Atractylodis Macrocephalae, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii, and fructus Mori.
The pharmacological properties of the traditional Chinese medicinal materials are as follows:
root of red-rooted salvia: the medicine has bitter property, is slightly cold, returns to heart, and liver meridian, and the radix salviae miltiorrhizae can dispel and dispel the heat, is slightly cold and clear, has the effects of removing blood stasis and relieving pain, activating blood and dredging meridian, clearing heart fire and relieving restlessness, and is used for irregular menstruation, amenorrhea and dysmenorrhea, obstruction and accumulation, thoracoabdominal stabbing pain, heat arthralgia pain, sore and sore pain, vexation and insomnia; hepatosplenomegaly and angina pectoris.
Rhodiola rosea: the medicine has sweet and bitter properties, can calm and smooth the lung and heart channels, and the rhodiola rosea has sweet and bitter taste, calms and cool, tonifies and has the effects of tonifying qi, relieving asthma, promoting blood circulation and dredging collaterals, and is especially suitable for patients with symptoms caused by qi deficiency, tiredness, chronic cough, deficiency asthma, qi deficiency, blood stasis and unsmooth blood vessels and heat. It has the functions of invigorating qi, promoting blood circulation, dredging meridian and relieving asthma.
Corn silk: sweet in flavor, pacify and enter liver, gall bladder, kidney and bladder meridians. Has diuretic and cholagogic effects, and also has effects in lowering blood pressure, lowering blood sugar, and treating chronic nephritis.
Ligusticum wallichii: pungent and warm properties, enter liver, gall bladder and pericardium meridian, chuan Xiong Xin Xianghang dispels heat and unblocks, ascending head and top, descending blood and sea, inner moving blood and qi, and outer dispelling wind-cold. It is indicated for pain due to blood stasis and qi stagnation with strong blood activating effect, and is most suitable for people with cold syndrome, and is known as qi-flowing in blood by the former. It contains alkaloid, volatile oil, phenols, lactone, vitamin A, folic acid, sucrose, sterol, fatty oil, etc., and has effects of promoting blood circulation, activating qi-flowing, dispelling pathogenic wind, and relieving pain.
Gastrodia elata Blume: mild nature, entering liver meridian. Can be used for treating convulsion, headache, apoplexy, etc. due to deficiency of liver. Can also improve poor blood circulation, smooth qi and blood, and has certain improving effect on symptoms such as joint disorder.
Eucommia ulmoides: sweet and warm nature, nourishing liver and kidney, strengthening tendons and bones, preventing miscarriage, and can be used for treating lumbago due to kidney deficiency, tendons and bones weakness, blood leakage during pregnancy, fetal movement, and hypertension. Compendium of materia Medica: eucommia ulmoides, ancient formula only nourishes kidney, but Wang Haogu is a liver meridian qi-flowing medicine, moistens liver dryness, nourishes liver deficiency, and is not yet developed by the shake. Liver governs tendons and kidney governs bones, kidney-qi is sufficient to strengthen bones, liver-qi is sufficient to strengthen tendons, and both are tendons. Du Zhong is purple and moist in color and flavor Gan Weixin, which is warm and flat, sweet and warm in nature and nourish the lung and nourish the kidney, so it can enter liver and tonify kidney, and son can make mother-son also.
Flower of pseudo-ginseng: is the essence of the whole plant of the pseudo-ginseng, is rich in effective components such as panaxadiol type pseudo-ginseng saponin, flavone, polysaccharide and the like, has the effects of cooling blood, reducing blood pressure, regulating lipid, regulating immunity, promoting blood circulation, promoting health, resisting aging, diminishing inflammation, easing pain, improving sleep, expanding crown, resisting allergy, promoting synthesis of serum protein, DNA and RNA, expelling toxin, nourishing face and resisting bleeding. The total arasaponin can obviously inhibit the formation of aortic intimal plaque of experimental atherosclerosis.
And (3) chrysanthemum: bitter in taste, sweet in flavor, slightly cold in nature, good in property, and capable of invigorating lung and liver meridian, dispelling wind and clearing heat, calming liver and improving eyesight, and clearing heat and detoxicating. Is mainly used for treating wind-heat type common cold, headache, dizziness, conjunctival congestion, eye pain, dim eyesight, sore, carbuncle and toxic swelling.
Semen cassiae: sweet, bitter and salty in taste, slightly cold in nature, enters liver and large intestine meridians, has the effects of clearing heat and improving eyesight, and relaxing bowel, and is used for treating conjunctival congestion and pain, photophobia and excessive tears, headache and dizziness, dim eyesight and constipation.
Momordica grosvenori: sweet in flavor, cool in nature, enter lung and spleen meridians, and has the effects of clearing lung-heat, relieving sore throat, resolving phlegm, relieving cough, relaxing bowel and relieving constipation, and mainly treating cough due to lung-heat and phlegm inflammation.
Radix astragali: the drug property is sweet and slightly warm, enters spleen and lung meridians, gan Wenbu L, sweet and slightly excreted, slightly warm for raw use, and warm for honey moxibustion, entering spleen and lung meridians, mainly strengthening healthy qi and eliminating pathogenic factors. It is good at tonifying middle-jiao qi, promoting the production of qi and clearing yang, tonifying lung qi, invigorating stomach and consolidating exterior, and can be used for treating spleen-lung qi deficiency, sinking middle-jiao qi, qi failing to control blood, spontaneous perspiration and night sweat, etc., and also for treating sore and ulcer due to deficiency of qi and blood, and qi deficiency and edema, dysuria.
White atractylodes rhizome: bitter in property, sweet in property, warm in nature, entering spleen and stomach meridians, and Bai Zhu is sweet in tonifying, excreting, bitter in flavor and warm in nature, and mainly has the actions of warming, tonifying and strengthening body resistance, and also can dispel water dampness. It is good at invigorating qi and spleen, eliminating dampness and promoting diuresis, and preventing abortion, and can be used for treating spleen and stomach qi deficiency, spleen deficiency edema, phlegm retention, spontaneous perspiration due to exterior deficiency, and fetal movement. It contains volatile oil such as atractylone, atractylol, atractylther, du Songnao, atractylenolide, du Songnao, and atractylenolide I-IV, and Bighead atractylenolide compound, and contains fructose, inulin, atractylenolide polysaccharide, various amino acids, atractylenolide, and vitamin A, and has effects of invigorating spleen, invigorating qi, eliminating dampness, promoting diuresis, suppressing sweating, and preventing miscarriage.
Gorgon fruit: sweet and astringent in flavor, and flat. The semen euryales is sweet, astringent and astringent, calm but not deviated, has mild efficacy, can tonify spleen and remove dampness, benefit kidney and arrest spontaneous emission, has the functions of tonifying but not greasy, astringing but not retaining dampness, and is mainly used for treating spleen deficiency and chronic diarrhea and deficiency of kidney with the symptoms of lower energizer failing to consolidate. It contains starch, protein, fat, carbohydrate, calcium, phosphorus, ferrum, thiamine, riboflavin, ni Gu Suan, ascorbic acid, etc., and has effects of invigorating kidney, stopping nocturnal emission, invigorating spleen, relieving diarrhea, removing dampness, and stopping leukorrhagia.
Herb of plantain: sweet and cold nature, good liver, kidney and bladder meridians, diuresis, heat-clearing, eyesight-improving, phlegm-resolving and cough-relieving.
Hawthorn fruit: sour and sweet in flavor, slightly warm in nature, and enters spleen, stomach and liver meridians. Has effects in invigorating stomach, resolving food stagnation, and regulating hyperlipidemia.
Lycium ruthenicum Murr: the lycium ruthenicum contains multiple nutritional ingredients such as protein, vitamins, minerals and the like, has high edible value, and the fruits of the lycium ruthenicum also contain rich anthocyanin ingredients, and has the functions of resisting oxidation and resisting allergy
Mulberry: mulberry, fructus Mori Gan Hanqing, with effects of tonifying, nourishing and benefiting the body, is used for treating heart, liver and kidney meridians. It is good at nourishing yin and blood and treating yin and blood deficiency; it can nourish yin, clear heat and promote fluid production, treat thirst due to fluid consumption and diabetes, moisten intestines to relieve constipation, and treat constipation due to intestinal dryness. It contains saccharide, tannic acid, malic acid, vitamins (C, B1, B2, A), carotene, various fatty acids, phosphoric acid, protein, rutin, alcohols, and microelements such as zinc and manganese. Has effects in nourishing yin, tonifying blood, promoting salivation, and moistening dryness.
The traditional Chinese medicine science considers that the root of hypertension is imbalance of yin and yang, the symptoms of the disease are endogenous wind, phlegm and blood stasis, and the hypertension is a systemic disease characterized by continuously increasing systemic arterial blood pressure in combination with modern medical analysis, and patients with hypertension often have atherosclerosis, atheromatous plaque formation, lumen stenosis, high blood viscosity, microcirculation disturbance and blood coagulation abnormality.
Blood lipid levels are generally classified into "phlegm" and "deficiency" in traditional Chinese medicine, and are greatly related to eating inadequacy, ataxia, excessive weakness, etc. of patients, blood lipid levels are generally negative, viscous and deposited, if the blood lipid levels are too high in the body of the patient, the occurrence of stickiness and deposition of blood and the like can be caused, and then qi and blood operations are blocked, blood stasis is caused, and once phlegm dampness and blood stasis are combined, similar bad symptoms exist as those of atherosclerosis in modern medicine, and hypertension can be caused secondarily. Moreover, in combination with modern medical analysis, hyperlipidemia is closely related to liver, which secretes carrier protein for transporting lipid, and synthetic lecithin for decomposing, digesting or absorbing excessive cholesterol, etc., and when it is abnormal, metabolic disorder occurs, leading to fat accumulation in serum, and causing high blood lipid content in vivo. Moreover, the symptoms of liver in patients with hyperlipidemia are mostly deficiency of yin fluid in liver, and balance of yin and yang is broken.
Hyperuricemia refers to a condition of normal purine diet in which blood uric acid levels are higher than 420. Mu. Mol/L in men and higher than 360. Mu. Mol/L in women, and is referred to as hyperuricemia. Uric acid is excessively high for a long time, and the saturation degree in blood is exceeded, so that the symptoms of red, swelling, heat and pain of joints are caused; urinary system stones, even renal failure, can also result. Currently, several epidemiological studies have demonstrated that uric acid is an independent risk factor for the onset of hypertension, with a relative 25% increase in blood uric acid levels of 59.5 μmol/L. Research proves that hyperuricemia has causal relationship with original hypertension; blood lipid and haematuria are also related; also has correlation with coronary heart disease and kidney.
Therefore, the preparation method selects and prepares medicines from the aspects of clearing cardiovascular stasis, reducing blood pressure, reducing blood fat, reducing uric acid, conditioning liver, kidneys and the like, and is assisted with systematically combined strengthening body resistance and strengthening body resistance medicines to improve the current situation of organisms.
(1) The effective components of the red sage root, the gastrodia tuber, the notoginseng flower, the szechuan lovage rhizome, the rhodiola root and the corn silk are matched with each other to enter the blood channel and the lung, the effective components of the red sage root, the gastrodia tuber, the notoginseng flower, the szechuan lovage rhizome, the rhodiola root and the corn silk enter the blood channel and the heart, return to the heart, dredge and clear the blood vessel, prevent thrombus formation and gradually eliminate thrombus, and play a role in activating blood and dissolving stasis.
(2) The chrysanthemum and the cassia seed are matched with each other and enter the liver to play a role in nourishing and protecting the liver.
(3) The astragalus root, the bighead atractylodes rhizome (one of the four monarch fruits in the traditional Chinese medicine) and the gorgon euryale seed are matched together to play roles in protecting and soothing the stomach, promoting the production of body fluid and moistening dryness and strengthening the spleen and the kidney, and the stomach is stimulated to play a role in conditioning due to the matching of other medicines.
(4) The black matrimony vine, mulberry, eucommia bark and the mutual coordination are used to play roles in nourishing yin, tonifying kidney and nourishing kidney.
(5) The Chinese medicinal composition is prepared from the Chinese medicinal herbs, has the effects of clearing heat, promoting urination, removing toxicity and resolving phlegm, and also has the effect of relieving and resolving the toxicity of other medicaments.
The combined action of the medicines not only has the effects of reducing blood pressure, blood fat and uric acid, but also can fundamentally improve the discomfort of the body and realize the homeostasis and rebalancing of the organism.
Compared with the prior art, the embodiment of the application has at least the following advantages or beneficial effects:
the medicine provided by the application can effectively reduce blood pressure, blood fat and blood uric acid, and condition the organism to reach normal health level, and the later period does not need to rely on the medicine.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application more clear, the technical solutions in the embodiments of the present application will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
It should be noted that, in the case of no conflict, the embodiments and features in the embodiments may be combined with each other. The present application will be described in detail with reference to specific examples.
The embodiment of the application provides a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, which comprises the following traditional Chinese medicinal materials: radix Salviae Miltiorrhizae, radix Rhodiolae, stigma Maydis, rhizoma Chuanxiong, rhizoma Gastrodiae, cortex Eucommiae, flos Notoginseng, flos Chrysanthemi, semen Cassiae, radix astragali, rhizoma Atractylodis Macrocephalae, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii, and fructus Mori.
The application starts with the preparation of medicines for clearing cardiovascular stasis and conditioning liver and kidney, and is assisted with systematically combined strengthening body resistance and strengthening body resistance medicines for improving the current situation of organisms. The organization coordination principle of the prescription is as follows: the red sage root, rhodiola root, corn silk and Ligusticum wallichii are used as monarch, gastrodia tuber, eucommia bark, notoginseng flower, chrysanthemum and cassia seed are used as ministers, astragalus root, white atractylodes rhizome, gorgon euryale seed, plantain herb is used as adjuvant, and momordica grosvenori, haw, black matrimony vine and mulberry are used as guides. The above medicinal materials are nontoxic, have the proportion of components with slight temperature and moderate temperature accounting for 70%, and have the obvious characteristic of no injury to people and correction of diseases after long-term administration. The tissue cooperation of the medicines plays an obvious role in reducing blood pressure, blood fat, blood uric acid and the like, can radically improve the discomfort of the body and realize the steady state of the organism.
In some embodiments of the present application, the above-mentioned traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases comprises the following traditional Chinese medicinal materials in parts by weight: 6 to 10 parts of red sage root, 6 to 10 parts of rhodiola rosea, 6 to 10 parts of corn silk, 4 to 8 parts of szechuan lovage rhizome, 4 to 6 parts of tall gastrodia tuber, 5 to 7 parts of eucommia bark, 4 to 6 parts of sanchi flower, 5 to 7 parts of chrysanthemum, 4 to 8 parts of cassia seed, 4 to 8 parts of astragalus root, 4 to 8 parts of largehead atractylodes rhizome, 4 to 8 parts of gordon euryale seed, 4 to 8 parts of plantain herb, 4 to 6 parts of momordica grosvenori, 4 to 6 parts of hawthorn fruit, 5 to 8 parts of black matrimony vine and 5 to 8 parts of mulberry.
The traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, which is obtained by adopting the proportion, has better curative effect.
In some embodiments of the present application, the above-mentioned Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases comprises the following components in parts by weight: 6 parts of red sage root, 6 parts of rhodiola rosea, 10 parts of corn silk, 5 parts of ligusticum wallichii, 5 parts of gastrodia tuber, 5 parts of eucommia bark, 4 parts of pseudo-ginseng flower, 5 parts of chrysanthemum, 5 parts of semen cassiae, 5 parts of astragalus root, 8 parts of bighead atractylodes rhizome, 8 parts of gorgon fruit, 8 parts of plantain herb, 4 parts of momordica grosvenori, 6 parts of hawthorn, 5 parts of lycium ruthenicum and 5 parts of mulberry.
The traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases, which is obtained by adopting the proportion, has good curative effect on patients with high blood pressure and high blood fat and symptoms of heart urgency and dysphoria.
In some embodiments of the present application, the above-mentioned Chinese medicinal composition is any one of a tablet, a paste, a decoction, a powder, and a granule.
The preparation can be used for conveniently producing and circulating medicines.
In some embodiments of the present application, the method for preparing the powder comprises: the preparation method comprises respectively drying radix Salviae Miltiorrhizae, radix Rhodiolae, stigma Maydis, rhizoma Chuanxiong, rhizoma Gastrodiae, cortex Eucommiae, flos Notoginseng, flos Chrysanthemi, semen Cassiae, radix astragali, rhizoma Atractylodis Macrocephalae, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii, and fructus Mori, pulverizing, and mixing the pulverized powders of the above materials to obtain final powder.
The medicine powder prepared by the method can be used for drinking after brewing, and the production process is simple and cheap.
In some embodiments of the present application, the above-described comminution particle size is 50 mesh.
During actual production, the crushing grain size of the medicine is preferably set within 50 meshes, so that the medicine can be conveniently produced to release more effective components through crushing, and the medicine absorption and utilization efficiency is improved.
In some embodiments of the present application, the preparation method of the decoction includes: cutting Saviae Miltiorrhizae radix, radix Rhodiolae, notoginseng flos, fructus Siraitiae Grosvenorii, black matrimony vine, mori fructus, flos Chrysanthemi, eucommiae cortex, rhizoma Ligustici Chuanxiong, semen Cassiae, stigma Maydis, fructus crataegi, rhizoma Gastrodiae, radix astragali, atractylodis rhizoma and semen euryales, adding pulverized fresh herba plantaginis, decocting with water for 30-40min to obtain a mixed decoction, filtering the mixed decoction to remove dry matter, and obtaining final decoction.
The medicinal decoction prepared by the method is prepared by fully and co-dissolving various high-molecular medicinal components into the medicinal liquid through decoction, and the crushed fresh plantain herb is added, so that the effective components for clearing heat and promoting urination in the medicament can be fully released and reserved, and the medicinal decoction with excellent effect is obtained.
In some embodiments of the present application, the preparation method of the tablet comprises: pulverizing Saviae Miltiorrhizae radix, radix Rhodiolae, stigma Maydis, rhizoma Ligustici Chuanxiong, rhizoma Gastrodiae, eucommiae cortex, notoginseng flos, flos Chrysanthemi, semen Cassiae, radix astragali, atractylodis rhizoma, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii and Mori fructus at low temperature, sterilizing, and tabletting to obtain final pharmaceutical tablet.
The mode of crushing at low temperature and pressing into tablets is adopted, so that the tablet is convenient to use and can effectively preserve bioactive components in the medicine.
The features and capabilities of the present application are described in further detail below in connection with the examples.
Example 1
The embodiment provides a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, which comprises the following traditional Chinese medicinal materials in parts by weight: 6g of red sage root, 6g of rhodiola rosea, 10g of corn silk, 5g of ligusticum wallichii, 5g of gastrodia tuber, 5g of eucommia bark, 4g of pseudo-ginseng flower, 5g of chrysanthemum, 5g of cassia seed, 5g of astragalus root, 8g of bighead atractylodes rhizome, 8g of gorgon fruit, 8g of plantain herb, 4g of momordica grosvenori, 6g of hawthorn, 5g of lycium ruthenicum and 5g of mulberry.
The preparation process is as follows: respectively drying Saviae Miltiorrhizae radix, radix Rhodiolae, stigma Maydis, rhizoma Ligustici Chuanxiong, rhizoma Gastrodiae, eucommiae cortex, notoginseng flos, flos Chrysanthemi, semen Cassiae, radix astragali, atractylodis rhizoma, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii and Mori fructus, pulverizing into 50 mesh powder, and mixing the pulverized powders of the above materials to obtain final medicinal powder.
Example 2
The embodiment provides a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, which comprises the following traditional Chinese medicinal materials in parts by weight: 10g of red sage root, 8g of rhodiola rosea, 6g of corn silk, 8g of ligusticum wallichii, 4g of gastrodia tuber, 6g of eucommia bark, 4g of pseudo-ginseng flower, 6g of chrysanthemum, 4g of cassia seed, 7g of astragalus root, 5g of bighead atractylodes rhizome, 5g of gorgon fruit, 5g of plantain herb, 6g of momordica grosvenori, 4g of hawthorn, 6g of lycium ruthenicum and 6g of mulberry.
The preparation process is as follows: cutting Saviae Miltiorrhizae radix, radix Rhodiolae, notoginseng flos, fructus Siraitiae Grosvenorii, black matrimony vine, mori fructus, flos Chrysanthemi, eucommiae cortex, rhizoma Ligustici Chuanxiong, semen Cassiae, stigma Maydis, fructus crataegi, rhizoma Gastrodiae, radix astragali, atractylodis rhizoma and semen euryales, adding pulverized fresh herba plantaginis, decocting with water for 30min to obtain a mixed decoction, filtering the mixed decoction to remove dry matter, and obtaining final medicinal decoction.
Example 3
The embodiment provides a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, which comprises the following traditional Chinese medicinal materials in parts by weight: 8g of red sage root, 10g of rhodiola rosea, 6g of corn silk, 4g of ligusticum wallichii, 4g of gastrodia tuber, 7g of eucommia bark, 5g of pseudo-ginseng flower, 7g of chrysanthemum, 8g of cassia seed, 4g of astragalus root, 4g of bighead atractylodes rhizome, 4g of gorgon fruit, 4g of plantain herb, 5g of momordica grosvenori, 4g of hawthorn, 8g of lycium ruthenicum and 8g of mulberry.
The preparation process is as follows: cutting Saviae Miltiorrhizae radix, radix Rhodiolae, notoginseng flos, fructus Siraitiae Grosvenorii, black matrimony vine, mori fructus, flos Chrysanthemi, eucommiae cortex, rhizoma Ligustici Chuanxiong, semen Cassiae, stigma Maydis, fructus crataegi, rhizoma Gastrodiae, radix astragali, atractylodis rhizoma and semen euryales, adding pulverized fresh herba plantaginis, decocting with water for 40min to obtain a mixed decoction, filtering the mixed decoction to remove dry matter, and obtaining final medicinal decoction.
Example 4
The embodiment provides a traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases, which comprises the following traditional Chinese medicinal materials in parts by weight: 9g of red sage root, 9g of rhodiola rosea, 8g of corn silk, 6g of ligusticum wallichii, 6g of gastrodia tuber, 5g of eucommia bark, 6g of pseudo-ginseng flower, 5g of chrysanthemum, 4g of cassia seed, 4g of astragalus root, 4g of bighead atractylodes rhizome, 6g of gorgon fruit, 6g of plantain herb, 5g of momordica grosvenori, 5g of hawthorn, 7g of lycium ruthenicum and 5g of mulberry.
The preparation process is as follows: pulverizing Saviae Miltiorrhizae radix, radix Rhodiolae, stigma Maydis, rhizoma Ligustici Chuanxiong, rhizoma Gastrodiae, eucommiae cortex, notoginseng flos, flos Chrysanthemi, semen Cassiae, radix astragali, atractylodis rhizoma, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii and Mori fructus at low temperature, sterilizing, and tabletting to obtain final pharmaceutical tablet each 5g.
Typical cases:
case 1: men, 36 years old, had a condition prior to the non-use of the present prescription: (1) hypertension, sometimes constipation, is treated with antihypertensive drugs twice a day; (2) triglyceride index (TG) 1.8mmol/L; (3) blood Uric Acid (UA) 567. Mu. Mol/L; (4) duodenal ulcer. The medicine provided in the example 1 is used for improving the condition after three treatment courses (one treatment course is 10 days, three times a day, each time 5g is taken after meal, and the dosage of the antihypertensive medicine is reduced by half, so that the stool is smooth; (2) the triglyceride index returns to normal (TG) by 1.3mmol/L; (3) the blood uric acid level returns to normal (UA) 401 mu mol/L; (4) the duodenal ulcer disappears, and no recurrence occurs after healing.
Case 2: women, 45 years old, had a condition before the current prescription was not used: (1) hypertension is treated by using antihypertensive drugs twice a day in the morning and evening; (2) triglyceride index (TG) 1.7mmol/L; (3) uric Acid (UA) 466. Mu. Mol/L; (4) duodenal ulcer. The drug of example 2 was used to improve the condition after three courses (one course is 10 days, three times a day, 200mL each): (1) the dosage of the antihypertensive drug is reduced by 50%; (2) the triglyceride index returns to normal (TG) by 1.4mmol/L; (3) restoration of blood uric acid level (UA) 381. Mu. Mol/L; (4) the duodenal ulcer condition disappeared. The effect is obvious after the medicine is continuously consolidated and taken.
Case 3: men, age 46, condition before the current prescription is not used: (1) blood pressure was found to be slightly higher (systolic 146 mmhg and diastolic 95 mmhg). (2) Triglyceride index (TG) 4.13mmol/L. (3) Uric Acid (UA) 577. Mu. Mol/L. (4) r-glutamyl transferase (GGT) 157U/L, severe fatty liver. The drug of example 2 was used to improve the condition after two courses (one course was 10 days, three times a day, 200mL each): (1) the blood pressure was restored to normal (diastolic pressure 85 mmHg, systolic pressure 136 mmHg). (2) The triglyceride index returns to normal (TG) 1.3mmol/L. (3) The blood uric acid level returns to normal (UA) 396. Mu. Mol/L. (4) r-glutamyl transferase (GGT) 51U/L, mild fatty liver. No repeated condition exists after healing.
Case 4: men, 54 years old, had a condition prior to the non-use of the present prescription: (1) the antihypertensive drug felodipine sustained release tablet is used for treating hypertension, and the sustained release tablet is 10 mg-5 mg, so that the excrement is difficult. (2) Triglyceride index (TG) 3.2mmol/L. (3) Blood Uric Acid (UA) 592. Mu. Mol/L. (4) Left atrial enlargement (LA) 42mm. The drug of example 3 was used to improve the condition after three courses (one course was 10 days, three times a day after meals, 200mL each time). (1) The dosage of the antihypertensive drug is reduced to 2.5 mg of the felodipine sustained-release tablet which is taken once every other day, and the stool is smooth. (2) The triglyceride index returns to normal (TG) 1.6mmol/L. (3) The blood uric acid level was recovered to be normal (UA) 401. Mu. Mol/L. (4) Left atrial gauge (LA) 32mm. The repeated situation is reproduced after healing. The treatment course is consolidated and used every month, and is not repeated.
Case 5: men, 62 years old, had a condition prior to the non-use of the present prescription: (1) hypertension has been caused by insomnia for more than ten years, and various antihypertensive drugs are replaced. (2) Triglyceride index (TG) 3.8mmol/L. (3) Blood Uric Acid (UA) 542. Mu. Mol/L. The drug provided in example 4 was used to improve the condition after three courses (one course was 10 days, taken three times a day, 4-6 tablets each time). (1) The antihypertensive drug is matched, so that the blood pressure is stable, and the sleep is improved. (2) The triglyceride index returns to normal (TG) 1.7mmol/L. (3) The blood uric acid level returns to normal (UA) 422. Mu. Mol/L. The repeated situation is reproduced after healing. The treatment course is consolidated and used every month, and is not repeated.
In summary, the embodiment of the application provides a second traditional Chinese medicine group for reducing blood pressure, blood fat and uric acid, which is prepared by selecting organs such as clearing cardiovascular stasis and conditioning liver, and the like, and is assisted with systematically combined strengthening body resistance and strengthening body resistance medicines to improve the current situation of organisms. The preparation method adopts the mutual coordination of the root of red-rooted salvia, the tall gastrodia tuber, the sanchi flower, the szechuan lovage rhizome, the rhodiola root and the corn silk, returns to the heart, the active ingredients of the preparation enter the heart and the lung of blood, the active ingredients of the preparation enter the cardiovascular system, the return to the heart, dredge and clear the blood vessels, prevent the thrombus from forming and gradually eliminate the thrombus, and play a role in activating blood and dissolving stasis. The chrysanthemum and the cassia seed are matched with each other and enter the liver to play a role in nourishing and protecting the liver. The astragalus root, the bighead atractylodes rhizome (one of the four monarch fruits in the traditional Chinese medicine) and the gorgon euryale seed are matched together to play roles in protecting and soothing the stomach, promoting the production of body fluid and moistening dryness and strengthening the spleen and the kidney, and the stomach is stimulated to play a role in conditioning due to the matching of other medicines. The black matrimony vine, mulberry, eucommia bark and the mutual coordination are used to play roles in nourishing yin, tonifying kidney and nourishing kidney. The Chinese medicinal composition is prepared from herba Achillea Wilsonianae, and has effects of clearing heat, promoting urination, removing toxic substances, eliminating phlegm, and relieving and resolving toxicity of other medicines
The embodiments described above are some, but not all, of the embodiments of the present application. The detailed description of the embodiments of the present application is not intended to limit the scope of the application, as claimed, but is merely representative of selected embodiments of the application. All other embodiments, which can be made by one of ordinary skill in the art based on the embodiments herein without making any inventive effort, are intended to be within the scope of the present application.
Claims (8)
1. A traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases is characterized by comprising the following traditional Chinese medicinal materials: radix Salviae Miltiorrhizae, radix Rhodiolae, stigma Maydis, rhizoma Chuanxiong, rhizoma Gastrodiae, cortex Eucommiae, flos Notoginseng, flos Chrysanthemi, semen Cassiae, radix astragali, rhizoma Atractylodis Macrocephalae, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii, and fructus Mori.
2. The traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases according to claim 1, which is characterized by comprising the following traditional Chinese medicinal materials in parts by weight: 6 to 10 parts of red sage root, 6 to 10 parts of rhodiola rosea, 6 to 10 parts of corn silk, 4 to 8 parts of szechuan lovage rhizome, 4 to 6 parts of tall gastrodia tuber, 5 to 7 parts of eucommia bark, 4 to 6 parts of sanchi flower, 5 to 7 parts of chrysanthemum, 4 to 8 parts of cassia seed, 4 to 8 parts of astragalus root, 4 to 8 parts of largehead atractylodes rhizome, 4 to 8 parts of gordon euryale seed, 4 to 8 parts of plantain herb, 4 to 6 parts of momordica grosvenori, 4 to 6 parts of hawthorn fruit, 5 to 8 parts of black matrimony vine and 5 to 8 parts of mulberry.
3. The traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular diseases according to claim 2, which is characterized by comprising the following traditional Chinese medicinal materials in parts by weight: 6 parts of red sage root, 6 parts of rhodiola rosea, 10 parts of corn silk, 5 parts of ligusticum wallichii, 5 parts of gastrodia tuber, 5 parts of eucommia bark, 4 parts of pseudo-ginseng flower, 5 parts of chrysanthemum, 5 parts of semen cassiae, 5 parts of astragalus root, 8 parts of bighead atractylodes rhizome, 8 parts of gorgon fruit, 8 parts of plantain herb, 4 parts of momordica grosvenori, 6 parts of hawthorn, 5 parts of lycium ruthenicum and 5 parts of mulberry.
4. The Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases according to any one of claims 1 to 3, wherein the Chinese medicinal composition is any one of tablets, ointments, decoctions, powders, granules.
5. The Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases according to claim 4, wherein the preparation method of the powder comprises the following steps of: the preparation method comprises respectively drying radix Salviae Miltiorrhizae, radix Rhodiolae, stigma Maydis, rhizoma Chuanxiong, rhizoma Gastrodiae, cortex Eucommiae, flos Notoginseng, flos Chrysanthemi, semen Cassiae, radix astragali, rhizoma Atractylodis Macrocephalae, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii, and fructus Mori, pulverizing, and mixing the pulverized powders of the above materials to obtain final powder.
6. The Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases according to claim 5, wherein the pulverized particle size is 50 mesh.
7. The Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases according to claim 4, wherein the decoction is prepared by the following steps: cutting Saviae Miltiorrhizae radix, radix Rhodiolae, notoginseng flos, fructus Siraitiae Grosvenorii, black matrimony vine, mori fructus, flos Chrysanthemi, eucommiae cortex, rhizoma Ligustici Chuanxiong, semen Cassiae, stigma Maydis, fructus crataegi, rhizoma Gastrodiae, radix astragali, atractylodis rhizoma and semen euryales, adding pulverized fresh herba plantaginis, decocting with water for 30-40min to obtain a mixed decoction, filtering the mixed decoction to remove dry matter, and obtaining final decoction.
8. The Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases according to claim 4, wherein the preparation method of the tablet comprises the following steps: pulverizing Saviae Miltiorrhizae radix, radix Rhodiolae, stigma Maydis, rhizoma Ligustici Chuanxiong, rhizoma Gastrodiae, eucommiae cortex, notoginseng flos, flos Chrysanthemi, semen Cassiae, radix astragali, atractylodis rhizoma, semen euryales, herba plantaginis, fructus Siraitiae Grosvenorii, fructus crataegi, fructus Lycii and Mori fructus at low temperature, sterilizing, and tabletting to obtain final pharmaceutical tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310643162.6A CN116492428A (en) | 2023-06-01 | 2023-06-01 | A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310643162.6A CN116492428A (en) | 2023-06-01 | 2023-06-01 | A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116492428A true CN116492428A (en) | 2023-07-28 |
Family
ID=87328529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310643162.6A Pending CN116492428A (en) | 2023-06-01 | 2023-06-01 | A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116492428A (en) |
-
2023
- 2023-06-01 CN CN202310643162.6A patent/CN116492428A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN107362213B (en) | Composition with bowel relaxing function and preparation method thereof | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN105148077A (en) | Health preserving porridge with blood sugar decreasing effect | |
| CN104958646A (en) | Chinese medicinal preparation for relaxing bowels and preparation method thereof | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN102512615A (en) | Traditional Chinese medicinal composition used for cancer recovery stage | |
| CN103989970B (en) | A kind of Chinese medicine composition treating hypertension | |
| CN105687788A (en) | Pharmaceutical composition capable of softening blood vessels and application thereof | |
| CN111135235A (en) | A composition for preventing and relieving acute alcoholism or alcoholic intoxication | |
| CN103202956A (en) | Antihypertensive life-preserving health-care medicinal liquor | |
| CN109224021A (en) | Treat diabetes, the health protecting tea of lowering blood pressure and blood fat and preparation method | |
| CN106860814B (en) | Health food composition for improving female frequent micturition and urinary incontinence and preparation method and application thereof | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN114081928A (en) | Traditional Chinese medicine composition for benefiting qi, promoting production of body fluid and reducing blood sugar and preparation method thereof | |
| CN116492428A (en) | A Chinese medicinal composition for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN104857121A (en) | Drug combination for curing hyperlipidemia and application thereof | |
| CN105250758A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN105169078A (en) | Traditional Chinese medicinal composition for treating diabetes | |
| CN104984150A (en) | Preparing technology of health maintaining porridge with blood pressure reducing effect | |
| CN104258351A (en) | Traditional Chinese medicine preparation for treating alcoholic cardiomyopathy and preparation method of preparation | |
| CN114767794B (en) | Traditional Chinese medicine for treating arterial plaque | |
| CN105343688A (en) | Medicine composition for treating myocardial infarction and application thereof | |
| CN118078920A (en) | Preparation for promoting blood circulation, removing blood stasis, dissolving thrombus and reducing three highs and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |